Market Intelligence, Clinical Progress, and High-Purity Reagents for Alpha-1B Adrenergic Receptor Targeted Therapy Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ADRA1B drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Stable Cell Line) | ADRA1B Overexpressing Stable Cell Line Full-length human receptor, HEK293 background, Membrane preparation (>95% purity), Endotoxin <1EU/ug, Sequence Verified. |
View ADRA1B Products |
| Gene Delivery (Lentivirus) | ADRA1B Lentivirus Premade Particles High titer (>10^8 TU/ml), Puromycin selection marker, Full-length ORF with native glycosylation. |
View ADRA1B Products |
| Gene Expression (ORF Clone) | ADRA1B Promise-ORF Full-length ORF, Sequence Verified, for transient or stable expression. |
View ADRA1B Products |
| Benchmark Ab | Anti-ADRA1B Reference Antibody Recombinant rabbit monoclonal positive control, Sequence verified, Endotoxin controlled. |
View ADRA1B Products |
| Validator (siRNA) | ADRA1B siRNA Set Three unique sequences for knockdown verification, HPLC purified. |
View ADRA1B Products |
| Related Target A | ADRA1A (Alpha-1A Adrenergic Receptor) Essential subtype for selectivity screening; 70% homology to ADRA1B. |
View ADRA1A Products |
| Related Target B | ADRA1D (Alpha-1D Adrenergic Receptor) Critical for counter-screening off-target cardiovascular effects. |
View ADRA1D Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Subtype Selectivity (ADRA1A/B/D discrimination) | Human ADRA1A, ADRA1B, ADRA1D ortholog stable cell lines available; Sequence verified by mass spec; HEK293 expressed. |
| GPCR Conformational Integrity | Lentivirus-transduced HEK293 cells preserve native membrane topology and Gq/11 coupling; Calcium flux validated format. |
| Species Cross-reactivity (Cyno/Mouse) | Human/Cynomolgus monkey/Rat ADRA1B stable lines available for preclinical translation; Theoretical MW cross-checked. |
| False Positives / Specificity Control | Validated siRNA included for target-specific signal attenuation; Negative control cell lines available. |
Live ADRA1B R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
ADRA1B (Alpha-1B adrenergic receptor) therapeutics are undergoing a significant transition. Historically dominated by non-selective small-molecule alpha-blockers for hypertension and benign prostatic hyperplasia (BPH), the clinical focus is now shifting toward exquisite subtype selectivity. While first-generation therapies exhibit off-target cardiovascular liabilities (e.g., orthostatic hypotension), the next R&D wave pursues highly selective allosteric modulators, biased ligands, and biologic modulators. Emerging indications include prostate cancer, tissue fibrosis, neuroinflammation, CNS disorders (PTSD, anxiety, depression), and heart failure. The critical bottleneck is the availability of conformationally intact, cell-based assay systems that can distinguish ADRA1B pharmacology from its highly homologous family members ADRA1A and ADRA1D.
Competitive Modality & Indication Snapshot
The following table summarizes the competitive landscape across major therapeutic modalities targeting ADRA1B:
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Antagonists | Pfizer, Roche, Sanofi, Generic Manufacturers | Hypertension, BPH, PTSD (repurposing) | Subtype Selectivity Panel (Need ADRA1A/ADRA1D counter-screens) |
| Biased Ligands | Biohaven, NIMH | Anxiety, Depression | Pathway-selective Reporting (Need stable GPCR cell lines with biosensors) |
| Allosteric Modulators | Academic Consortia, Biotech | Heart Failure, CNS Disorders | Orthosteric vs Allosteric Binding Assays (Need full-length conformational variants) |
| Biologic / mAb | Academic/Biotech Consortia | Prostate Cancer, Fibrosis | Cell-Based Binding & Calcium Flux (Lentivirus stable lines preserving native conformation) |
| Radioligand / PET Tracer | Molecular Imaging Developers | Neurology, Oncology | High-Purity Membrane Preps from Overexpressing Cells |
Key Mutations & Polymorphisms
Notable ADRA1B variants include rs8192448 (UniProt VAR_019510), a reported single-nucleotide polymorphism that may influence receptor pharmacology. While its functional impact is not fully characterized, awareness of such variants is important for assay design and compound screening in diverse genetic backgrounds.